Modifying effects of flumequine on dimethylnitrosamineinduced hepatocarcinogenesis in heterozygous p53 deficient CBA mice

Journal of Toxicologic Pathology

Volumn 14, Issue 2, 2001, Pages 135-143

  Takizawa, Tamotsu ^a   Mitsumori, Kunitoshi ^a,b   Takagi, Hisayoshi ^a   Onodera, Hiroshi ^a   Yasuhara, Kazuo ^a   Tamura, Toru ^a   Hirose, Masao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Flumequine; Hepatocarcinogenesis. Heterozygous p53 deficient mice

Indexed keywords

EID: 0005017897     PISSN: 09149198     EISSN: 09149198     Source Type: Journal    
DOI: 10.1293/tox.14.135     Document Type: Article

References (21)

1. Greenwood D. Activity of flumequine against Escherichia coll: in vitro comparison with nalidixic and oxolinic acids. Antimicrob Agents Chemother 1978; 13: 478-483.
2. WHO. Toxicological evaluation of certain veterinary drugs residues in food. The forty-second meeting of the joint FAO/ WHO expert committee on food additives (JECFA), WHO Food Additives Series, 1994; No. 33, 35-54.
3. WHO. Toxicological evaluation of certain veterinary drugs residues in food. The forty-eighth meeting of the joint FAO/ WHO expert committee on food additives (JECFA), WHO Food Additives Series. 1997; No. 39, 63-75.
4. Yoshida M, Miyajima K, Shiraki K, Ando J, Kudoh K, Nakae D, Takahashi M, and Maekawa A. Hepatotoxicity and consequently increased cell proliferation are associated with flumequine hepatocarcinogenesis in mice. Cancer Lett 1999; 141: 99-107.
5. Fiala ES, Conaway CC, and Mathis JE. Oxidative DNA and RNA damage in the livers of Sprague-Dawley rats treated with the hepatocarcinogen 2-nitropropane. Cancer Res 1989; 49:5518-5522.
6. Dunnick JK, Hardisty JF, Herbert RA. Seely JC, FurediMachacek EM, Foley JE, Lacks GD, Stasiewicz S, and French JE. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous/)JJ-deficient (+/-) mice. Toxicol Pathol 1997; 25: 533-540.
7. Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, Kawasaki H, Yoshitake A, Wanibuchi H, Koide A, Mori Y, and Fukushima S. High susceptibility of p53 (+/-) knockout mice in N-butyl-N-(4-hydroxybuytl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 1998; 58 (Suppl. 1): 3808-381 1.
8. Tennant RW, French JE, and Spalding, JW, Identifying chemical carcinogens and assessing potential risk in shortterm bioassays using transgenic mouse models. Envion Health Persp 1995; 103: 942-950.
9. Tennant RW, Spalding J, and French JE. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res 1996; 356: 119-127.
10. Mitsumori K, Onodera H, Shimo T, Yasuhara K, Takagi H, Koujitani T, Hirose M, Maruyama C, and Wakana S. Rapid induction of uterine tumors with p53 point mutations in heterozygous p53 deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea. Carcinogenesis 2000; 21: 1039-1042.
11. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N. Suda Y, Abe S, Matsuo I, Ikawa Y, and Aizawa S. Enhanced proliferative potential in culture of cells from P53-JJ-deficient mice. Oncogene 1993; 8: 3313-3322.
12. Lowe SW, Schmiff EM, Smith SW, Osborne B A, and Jacks T. P53 is regulated for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
13. Lowe SW, Ruley HE, Jacks T, and Housman DE. P53mediated apoptosis modulates the cytotoxicity of anticancer sgents. Cell 1993; 74: 957-967.
14. Miyashita, T. Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, and Reed, JC. Tumor suppresor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 17991805.
15. Yin L, Ghebranious N, Chakraborty S, Sheehan CE, Ilic Z,and Sell S. Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo. Hepatology 1998; 27: 73-80.
16. Delker DA, Yano BL. and Gollapudi BB. Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero-and nullizygous transgenic p53 mice. Toxicol Sei 2000; 55: 361-369.
17. Sukata T, Ozaki K, Uwagawa S, Seki T, Wanibuchi H, Yamamoto S, Okuno Y, and Fukushima S. Organ-specific, carcinogen-induced increases in cell proliferation in p53deficient mice. Cancer Res 2000; 60: 74-79.
18. Diwan BA, Rice JM, Ohshima M, Ward JM, and Dove LF. Comparative tumor-promoting activities of phenobarbitalm amobarbital, barbital sodium, and barbituric acid on livers and other organs of male F344/NCr rats follwing initiation with N-nitrosodiethylamine. J Natl Cancer Inst 1985; 74: 509-516.
19. McConnell EE, Huff JE, Hejtmancik M, Peters AC, and Persing R. Toxicology and carcinogenesis studies of two grades of pentachlorophenol in B6C3F1 mice. Fundam Appl Toxicol 1991; 17: 519-532.
20. Sagartz JE, Curtoss SW, Bunch RT, Davila JC, Morris DL, and Alden CL. Phénobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice. Toxicologie Pathol 1998; 26: 492-500.
21. Spalding JW, French JE, Stasiewicz S. Furedi-Machacek M, Conner F, Tice RR, and Tennant RW. Responses of transgenic mouse lines p53 +/- and Tg AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci 2000; 53:213-223.